Quarterly report · Q1
4361.TEDINET S100T7MO
Period2023-12-01 → 2024-02-29
Filed2024-04-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.0bn | 2023-12-01 → 2024-02-29 | Cons. | Net sales |
| Revenue | ¥8.6bn | 2022-12-01 → 2023-11-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.1bn | 2022-12-01 → 2023-02-28 | Cons. | Net sales |
| Operating income | ¥68m | 2023-12-01 → 2024-02-29 | Cons. | Operating income |
| Operating income | ¥47m | 2022-12-01 → 2023-02-28 | Cons. | Operating income |
| Ordinary income | ¥67m | 2023-12-01 → 2024-02-29 | Cons. | Ordinary income |
| Ordinary income | ¥345m | 2022-12-01 → 2023-11-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥46m | 2022-12-01 → 2023-02-28 | Cons. | Ordinary income |
| Profit before tax | ¥67m | 2023-12-01 → 2024-02-29 | Cons. | Income before income taxes |
| Profit before tax | ¥46m | 2022-12-01 → 2023-02-28 | Cons. | Income before income taxes |
| Net income (owners) | ¥50m | 2023-12-01 → 2024-02-29 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥256m | 2022-12-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥41m | 2022-12-01 → 2023-02-28 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥50m | 2023-12-01 → 2024-02-29 | Cons. | Profit loss |
| Net income | ¥41m | 2022-12-01 → 2023-02-28 | Cons. | Profit loss |
| Total assets | ¥8.1bn | at 2024-02-29 | Cons. | Assets |
| Total assets | ¥8.3bn | at 2023-11-30 | Cons. | Assets |
| Total assets | ¥8.2bn | at 2023-02-28 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.4bn | at 2024-02-29 | Cons. | Liabilities |
| Total liabilities | ¥5.7bn | at 2023-11-30 | Cons. | Liabilities |
| Net assets / equity | ¥2.6bn | at 2024-02-29 | Cons. | Net assets |
| Net assets / equity | ¥2.6bn | at 2023-11-30 | Cons. | Net assets |
| Net assets / equity | ¥2.4bn | at 2023-02-28 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥906m | at 2024-02-29 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.0bn | at 2023-11-30 | Cons. | Cash and deposits |
| EPS (basic) | ¥40.79 | 2023-12-01 → 2024-02-29 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥209.88 | 2022-12-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥33.77 | 2022-12-01 → 2023-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 32.5% | at 2024-02-29 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.1% | at 2023-02-28 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q1r_E01006-000Pharmaceutical Productsreportable segment | revenue | 2023-12-01 → 2024-02-29 | ¥2.0bn |
| jpcrp040300-q1r_E01006-000Pharmaceutical Productsreportable segment | revenue external | 2023-12-01 → 2024-02-29 | ¥2.0bn |
| jpcrp040300-q1r_E01006-000Pharmaceutical Productsreportable segment | segment profit | 2023-12-01 → 2024-02-29 | ¥60m |
| jpcrp040300-q1r_E01006-000Real Estate Leasingreportable segment | revenue | 2023-12-01 → 2024-02-29 | ¥10m |
| jpcrp040300-q1r_E01006-000Real Estate Leasingreportable segment | revenue external | 2023-12-01 → 2024-02-29 | ¥10m |
| jpcrp040300-q1r_E01006-000Real Estate Leasingreportable segment | segment profit | 2023-12-01 → 2024-02-29 | ¥8m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-12-01 → 2024-02-29 | ¥2.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-12-01 → 2024-02-29 | ¥2.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-12-01 → 2024-02-29 | ¥68m |
| jpcrp040300-q1r_E01006-000Pharmaceutical Productsreportable segment | revenue | 2022-12-01 → 2023-02-28 | ¥2.0bn |
| jpcrp040300-q1r_E01006-000Pharmaceutical Productsreportable segment | revenue external | 2022-12-01 → 2023-02-28 | ¥2.0bn |
| jpcrp040300-q1r_E01006-000Pharmaceutical Productsreportable segment | segment profit | 2022-12-01 → 2023-02-28 | ¥39m |
| jpcrp040300-q1r_E01006-000Real Estate Leasingreportable segment | revenue | 2022-12-01 → 2023-02-28 | ¥10m |
| jpcrp040300-q1r_E01006-000Real Estate Leasingreportable segment | revenue external | 2022-12-01 → 2023-02-28 | ¥10m |
| jpcrp040300-q1r_E01006-000Real Estate Leasingreportable segment | segment profit | 2022-12-01 → 2023-02-28 | ¥8m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-12-01 → 2023-02-28 | ¥2.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-12-01 → 2023-02-28 | ¥2.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-12-01 → 2023-02-28 | ¥47m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 333
| Item | Context | Value | Unit |
|---|---|---|---|
| Comprehensive income attributable to non controlling interests | Prior1YTDDuration | － | JPY |
| Comprehensive income attributable to non controlling interests | CurrentYTDDuration | － | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 2042442000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E01006-000RealEstateLeasingReportableSegmentMember | 9547000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 2051990000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 2051990000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E01006-000PharmaceuticalProductsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E01006-000RealEstateLeasingReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 2042442000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E01006-000RealEstateLeasingReportableSegmentMember | 9547000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 2051990000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration | 2051990000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 38859000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E01006-000RealEstateLeasingReportableSegmentMember | 7645000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 46504000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1YTDDuration | 46504000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 1990333000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E01006-000RealEstateLeasingReportableSegmentMember | 9595000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 1999928000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 1999928000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E01006-000PharmaceuticalProductsReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E01006-000RealEstateLeasingReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 1990333000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E01006-000RealEstateLeasingReportableSegmentMember | 9595000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 1999928000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | CurrentYTDDuration | 1999928000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q1r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 59808000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q1r_E01006-000RealEstateLeasingReportableSegmentMember | 7693000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 67502000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | CurrentYTDDuration | 67502000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-04-10 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第123期第１四半期(自 2023年12月１日 至 2024年２月29日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)川口化学工業株式会社 | |
| Company name in english cover page | FilingDateInstant | Kawaguchi Chemical Industry Co., Ltd | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 山 田 秀 行 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |